Sequenziamento mediante pyrosequencing: un’analisi rapida e sensibile per la determinazione delle mutazioni di EGFR nel carcinoma polmonare non a piccole cellule
- 16 Downloads
Lung cancer is the most common tumor and one of the most aggressive, with rates of survival at 5 years of about 10% in most countries. Studies reported EGFR (Epidermal Growth Factor Receptor) gene activating mutations in 10–15% of NSCLC (Non Small Cell Lung Cancer) in the European population.
Molecular assessment of EGFR mutations became mandatory for gefitinib administration in NSCLC patients. Only tumors harboring at least one activating mutation in either exon 18, 19 or 21 are eligible for therapy with this drug.
Several methods are available in order to study EGFR mutations, such as direct sequencing and Real Time PCR. Pyrosequencing is a DNA sequencing technique based on the principle of sequencing-by-synthesis and it is characterized by a greater sensitivity compared to direct sequencing. We compared pyrosequencing with Real Time PCR, both combined with CE-IVD approved commercially available kits for EGFR analysis, in terms of effectiveness, economic and logistic impact.
In conclusion, although Real Time PCR has a greater sensitivity, pyrosequencing is an effective and reliable method, with an advantage in detecting new mutations whose clinical impact is yet unknown. More studies are needed in order to define which sensitivity level is really correlated to clinical response.
Unable to display preview. Download preview PDF.
- 5.Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology Provisional Clinical Opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29(15): 2121–7PubMedCrossRefGoogle Scholar
- 7.Determinazione AIFA 11/05/2010, G.U. n. 122, 27/05/2010Google Scholar
- 9.EGFR TKI Response® (Resistance) — Manuale d’uso versione 2010/10, Diatech Pharmacogenetics (Italy)Google Scholar
- 13.Marchetti A, Normanno N. Raccomandazioni per l’analisi mutazionale del gene EGFR nel carcinoma polmonare. AIOM-SIAPEC-IAP 2008Google Scholar
- 15.EGFR TKI Response® (Sensitivity) — Manuale d’uso versione 2010/11, Diatech Pharmacogenetics (Italy)Google Scholar
- 17.Schneider CP, Heidegener D, Schott-von-Römer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol 2008; 3(12): 1446–53PubMedCrossRefGoogle Scholar
- 24.Cohen V, Agulnik JS, Ang C, et al. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer 2010; 116(18): 4309–17PubMedCrossRefGoogle Scholar
- 38.Chen S, Chen Z, Guo A, et al. Detection of epidermal growth factor receptor mutations in non-small cell lung cancer tumor specimens from various ways by denaturing high-performance liquid chromatography (abstract). Zhongguo Fei Ai Za Zhi (Chinese journal of lung cancer) 2010; 13(9): 850AGoogle Scholar